Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 3, 2006

View Archived Issues

APD-791 antithrombosis agent advanced into preclinical development

NDA filing completed for Genasense plus chemotherapy for CLL

Adolor files IND to begin phase I with ADL-5859

Amylin acquires Ohio facility to manufacture exenatide LAR

GenVec sells myoblast cell therapy program to Mytogen

Aphios licenses vitamin D analogue from Boston University for prostate cancer

LS-104's therapeutic potential for Flt3-ITD positive leukemia

ABI-0043: ActivBiotics' lead preclinical compound against Gram-positive bacterial infections

New agents for endocrine-related disorders disclosed in recent patent literature

AN-0128: Potential antibacterial for a variety of dermatological infections

Novel chemokine CCR2B antagonists from AstraZeneca

Bactericidal profile of new carbacephems emerging from Blanca Pharmaceuticals

ETI-211 clears, protects against Staphylococcus aureus infection

Activity of CG-400549 against Staphylococcus aureus tested in vitro, in vivo

Cephalon completes acquisition of Zeneus

Promising antifungal activity seen with RBx-9050

DNAPrint Genomics acquires Ellipsis Biotherapeutics

Glenmark acquires Bouwer Bartlett

MicroIslet raises funds through sale of common stock

Pharming files for GRAS notification for human lactoferrin

Pharming completes rhC1INH dossier for compassionate use filings

Roche grants Tamiflu sublicense to Hetero Drugs

Discovery Laboratories to acquire Laureate Pharma's manufacturing operations

TD-2749 demonstrates prokinetic effect in healthy volunteers; TD-5108 begins human trials

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.